1216-Microbiota-Immunity Axis in Cancer Checkpoint Blockade

The research explores the critical link between the gut microbiota and the success of immune checkpoint blockade (ICB) in cancer treatment. It highlights how the presence of specific beneficial microbes and their metabolic byproducts, such as short-chain fatty acids, can enhance a patient's immune response against tumors. Conversely, factors like antibiotic use or a low-fiber diet can lead to microbial imbalances that undermine therapeutic efficacy and survival rates. The text also examines how the microbiome influences the development of immune-related adverse effects, such as colitis, which often occur during treatment. Furthermore, it discusses how dietary habits—ranging from high-fiber to high-fat intakes—interact with intestinal bacteria to modulate systemic immunity. Ultimately, the review identifies the gut-organ axis as a vital frontier for developing personalized strategies to improve cancer immunotherapy outcomes.References:Gladstone JL, Sonnenberg GF. Gut microbiota and metabolic control of immune checkpoint blockade in cancer. Cell Metab. 2026 May 25:S1550-4131(26)00156-7. doi: 10.1016/j.cmet.2026.04.018. Epub ahead of print. Erratum in: Cell Metab. 2026 Jun 10:S1550-4131(26)00234-2. doi: 10.1016/j.cmet.2026.06.008. PMID: 42184832; PMCID: PMC13267733.前往小宇宙评论区与主播互动